Product Description
Oxaliplatin is a type of chemotherapy drug. It is also called Eloxatin. It's a treatment for bowel cancer and some other types of cancer. You usually have oxaliplatin in combination with other chemotherapy drugs. It depends on the type of cancer you have as to which drugs you have it with. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/oxaliplatin-eloxatin)
Mechanisms of Action: DNA Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: Europe
Company Founding Year: 1973
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Mexico, Netherlands, Norway, Poland, Portugal, Puerto Rico, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 92
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Adenocarcinoma|Biliary Tract Cancer|Colic|Colorectal Cancer|Diffuse Large B-Cell Lymphoma|Esophageal Cancer|Gastrointestinal Cancer|Lymphoma, Non-Hodgkin|Pancreatic Cancer
Phase 2: Bladder Cancer|Breast Cancer|Chemical and Drug Induced Liver Injury|Cholangiocarcinoma|Digestive System Cancer|Esophageal Diseases|Gallbladder Cancer|Hepatic Veno-Occlusive Disease|Hepatocellular Carcinoma|Intestinal Diseases|Liver Cancer|Lung Cancer|Lymphoma, B-Cell|Pancreatic Ductal Carcinoma|Peritoneal Cancer|Squamous Cell Carcinoma|Stomach Diseases
Phase 1: Epilepsy|Muscle Spasticity|Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05476796 |
LOGICAN | P2 |
Recruiting |
Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer |
2026-01-01 |
41% |
2023-10-18 |
Primary Endpoints|Start Date|Treatments |
NCT06247956 |
SHR-8068-201-GC | P2 |
Active, not recruiting |
Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer|Squamous Cell Carcinoma |
2025-12-30 |
2% |
2025-09-04 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Treatments|Trial Status |
2025-520471-29-00 |
FCO-FOX-2024-01 | P3 |
Not yet recruiting |
Colorectal Cancer|Adenocarcinoma|Colic |
2030-12-31 |
|||
NCT06571461 |
HE072-006 | P3 |
Not yet recruiting |
Pancreatic Cancer |
2028-01-01 |
17% |
2024-11-27 |
Primary Endpoints|Treatments |
NCT06929624 |
SHR-A1912-301 | P3 |
Recruiting |
Diffuse Large B-Cell Lymphoma |
2027-03-01 |
71% |
2025-05-14 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT05144854 |
ONO-4538-113 | P3 |
Active, not recruiting |
Gastrointestinal Cancer |
2026-05-01 |
86% |
2024-09-06 |
Primary Completion Date|Primary Endpoints|Treatments |
NCT05253651 |
MOUNTAINEER-03 | P3 |
Recruiting |
Colorectal Cancer |
2026-04-03 |
42% |
2025-02-22 |
|
NCT04469556 |
PASS-01 | P2 |
Completed |
Pancreatic Cancer|Adenocarcinoma|Pancreatic Ductal Carcinoma |
2025-03-05 |
2026-02-21 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
CTR20200664 |
CTR20200664 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2023-06-08 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT05494060 |
EXPLORING | P2 |
Recruiting |
Esophageal Diseases|Adenocarcinoma|Gastrointestinal Cancer|Digestive System Cancer|Intestinal Diseases|Esophageal Cancer|Stomach Diseases |
2024-12-01 |
41% |
2023-11-08 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT04430738 |
SGNTUC-024 | P2 |
Active, not recruiting |
Gastrointestinal Cancer|Esophageal Cancer|Cholangiocarcinoma|Colorectal Cancer|Bladder Cancer|Adenocarcinoma |
2024-07-31 |
12% |
2025-09-10 |
Primary Endpoints |
2017-000927-29 |
CRC-PIPAC | P2 |
Active, not recruiting |
Colorectal Cancer|Peritoneal Cancer |
2020-01-31 |
2022-03-13 |
Treatments |
|
ACTRN12619001723178p |
2006-7041-83/hah | P1 |
Not yet recruiting |
Muscle Spasticity|Epilepsy |
2020-02-24 |
|||
NCT06258525 |
IIT2022-11-Gangi-SAMe | P2 |
Not yet recruiting |
Hepatic Veno-Occlusive Disease|Chemical and Drug Induced Liver Injury|Colorectal Cancer|Liver Cancer |
2028-04-01 |
2% |
2025-11-05 |
|
NCT07146646 |
CASE2225 | P2 |
Recruiting |
Gallbladder Cancer|Cholangiocarcinoma|Biliary Tract Cancer |
2027-02-01 |
2025-11-13 |
Primary Endpoints|Start Date|Treatments|Trial Status |
|
NCT06806033 |
GO45434 | P2 |
Recruiting |
Lymphoma, Non-Hodgkin|Lymphoma, B-Cell |
2027-01-31 |
12% |
2025-12-24 |
Primary Endpoints|Start Date|Study Completion Date|Treatments |
NCT06205485 |
NEO-RT | P3 |
Recruiting |
Colorectal Cancer |
2030-01-30 |
2024-08-14 |
Primary Endpoints|Start Date |
|
NCT06624085 |
GO44900 | P1 |
Recruiting |
Diffuse Large B-Cell Lymphoma |
2030-03-31 |
50% |
2025-06-05 |
Primary Completion Date|Primary Endpoints|Treatments |
2022-501181-22-01 |
STEREOPAC-001 | P2 |
Recruiting |
Pancreatic Cancer|Adenocarcinoma |
2032-10-01 |
2025-05-02 |
Treatments |
|
2023-509814-12-00 |
2023-509814-12-00 | P2 |
Recruiting |
Colorectal Cancer |
2031-03-31 |
2025-05-02 |
||
2020-003134-20 |
MEND-IT | P2 |
Active, not recruiting |
Colorectal Cancer |
2030-05-17 |
2022-03-13 |
Treatments |
|
NCT07281768 |
J25118 | P2 |
Not yet recruiting |
Adenocarcinoma|Colorectal Cancer |
2030-03-01 |
12% |
2025-12-16 |
Primary Endpoints|Treatments |
2024-516791-15-00 |
GO45434 | P2 |
Recruiting |
Diffuse Large B-Cell Lymphoma |
2029-04-30 |
2025-05-02 |
Treatments |
|
2025-523261-25-00 |
2025-523261-25-00 | P2 |
Not yet recruiting |
Colorectal Cancer |
2029-03-01 |
|||
NCT07437287 |
CROCOBIL | P3 |
Not yet recruiting |
Biliary Tract Cancer |
2030-04-01 |
30% |
2026-02-28 |
Primary Endpoints|Treatments |
